RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $393.49 million. The enterprise value is $177.54 million.
Important Dates
The next estimated earnings date is Tuesday, February 24, 2026, after market close.
| Earnings Date | Feb 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 41.12 million shares outstanding. The number of shares has increased by 7.62% in one year.
| Current Share Class | 41.12M |
| Shares Outstanding | 41.12M |
| Shares Change (YoY) | +7.62% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 75.85% |
| Float | 36.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.74 |
| Forward PS | 3.08 |
| PB Ratio | 1.42 |
| P/TBV Ratio | 1.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.74, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.74 |
| Quick Ratio | 11.29 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,393.79 |
Financial Efficiency
Return on equity (ROE) is -12.92% and return on invested capital (ROIC) is -9.87%.
| Return on Equity (ROE) | -12.92% |
| Return on Assets (ROA) | -9.18% |
| Return on Invested Capital (ROIC) | -9.87% |
| Return on Capital Employed (ROCE) | -15.89% |
| Revenue Per Employee | $285,311 |
| Profits Per Employee | -$71,747 |
| Employee Count | 498 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.40 |
Taxes
In the past 12 months, RxSight has paid $73,000 in taxes.
| Income Tax | 73,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.12% in the last 52 weeks. The beta is 1.14, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -73.12% |
| 50-Day Moving Average | 10.68 |
| 200-Day Moving Average | 11.57 |
| Relative Strength Index (RSI) | 32.42 |
| Average Volume (20 Days) | 708,783 |
Short Selling Information
The latest short interest is 4.42 million, so 10.76% of the outstanding shares have been sold short.
| Short Interest | 4.42M |
| Short Previous Month | 4.44M |
| Short % of Shares Out | 10.76% |
| Short % of Float | 12.04% |
| Short Ratio (days to cover) | 5.22 |
Income Statement
In the last 12 months, RxSight had revenue of $142.09 million and -$35.73 million in losses. Loss per share was -$0.88.
| Revenue | 142.09M |
| Gross Profit | 106.53M |
| Operating Income | -45.48M |
| Pretax Income | -35.66M |
| Net Income | -35.73M |
| EBITDA | -42.55M |
| EBIT | -45.48M |
| Loss Per Share | -$0.88 |
Full Income StatementBalance Sheet
The company has $227.52 million in cash and $11.57 million in debt, with a net cash position of $215.95 million or $5.25 per share.
| Cash & Cash Equivalents | 227.52M |
| Total Debt | 11.57M |
| Net Cash | 215.95M |
| Net Cash Per Share | $5.25 |
| Equity (Book Value) | 275.97M |
| Book Value Per Share | 6.72 |
| Working Capital | 261.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.66 million and capital expenditures -$3.54 million, giving a free cash flow of -$22.20 million.
| Operating Cash Flow | -18.66M |
| Capital Expenditures | -3.54M |
| Free Cash Flow | -22.20M |
| FCF Per Share | -$0.54 |
Full Cash Flow StatementMargins
Gross margin is 74.98%, with operating and profit margins of -32.01% and -25.15%.
| Gross Margin | 74.98% |
| Operating Margin | -32.01% |
| Pretax Margin | -25.10% |
| Profit Margin | -25.15% |
| EBITDA Margin | -29.95% |
| EBIT Margin | -32.01% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.62% |
| Shareholder Yield | -7.62% |
| Earnings Yield | -9.08% |
| FCF Yield | -5.64% |
Dividend DetailsAnalyst Forecast
The average price target for RxSight is $11.30, which is 18.08% higher than the current price. The consensus rating is "Hold".
| Price Target | $11.30 |
| Price Target Difference | 18.08% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 3.90% |
| EPS Growth Forecast (5Y) | -65.33% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 16.33 and a Piotroski F-Score of 3.
| Altman Z-Score | 16.33 |
| Piotroski F-Score | 3 |
